Jul 25, 2018
The FDA has approved AbbVie's Gonadotropin-Releasing Hormone (GnRH) antagonist Elagolix on Tuesday. FDA has given green light to the first oral treatment for endometriosis pain. The drug is branded as Orilissa, and is expected to be available in U.S. pharmacies in August. It will carry a list price of about $850 per...
Read More...
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper